Limited penetration of lopinavir and ritonavir in the genital tract of men infected with HIV-1 in Brazil

Therapeutic Drug Monitoring

Volumn 28, Issue 2, 2006, Pages 175-179

  Vergara, Tania R C ^a   Estrela, Rita C E ^b   Suarez Kurtz, Guilherme ^b   Schechter, Mauro ^a   Cerbino Neto, José ^a   Barroso, Paulo F ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

HIV 1; Lopinavir; Ritonavir; Semen; Viral load

Indexed keywords

LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG PENETRATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHUMAN; PRIORITY JOURNAL; SPERM; VIRUS LOAD; VIRUS STRAIN; VIRUS TRANSMISSION;

BIOLOGICAL AVAILABILITY; BRAZIL; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; PYRIMIDINONES; REGRESSION ANALYSIS; RITONAVIR; SEMEN; TIME FACTORS; UROGENITAL SYSTEM; VIRAL LOAD;

EID: 33748146444     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000180225.27008.8c     Document Type: Article

References (27)

1. Quinn TC. Global burden of the HIV pandemic. Lancet. 1996; 348:99-106.
2. Barroso PF, Schechter M, Gupta P, et al. Effect of antiretroviral therapy on HIV shedding in semen. Ann Intern Med. 2000;133:280-284.
3. Gupta P, Mellors J, Kingsley L, et al. High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and non-nucleoside reverse transcriptase inhibitors. J Virol. 1997; 71:6271-6275.
4. Kashuba ADM, Dyer JR, Kramer LM, et al. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1998;43:1817-1826.
5. Taylor S, Pereira AS. Antiretroviral drug concentrations in semen of HIV-1 infected men. Sex Transm Infect. 2001;77:4-11.
6. Kepler TB, Perelson AS. Drug concentration heterogeneity facilitates the evolution of drug resistance. Proc Natl Acad Sci. 1998;95:11514-11519.
7. Pereira AS, Kashuba AD, Fiscus AS, et al. Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden. J Infect Dis. 1999;180:2039-2043.
8. Taylor S, Back DJ, Drake SM, et al. Antiretroviral drug concentrations in semen of HIV- infected men: differential penetration of indinavir, ritonavir, and saquinavir. J Antimicrob Chemother. 2001;48:351-354.
9. Sankatsing SU, Droste J, Burger D, et al. Limited penetration of lopinavir into seminal plasma of HIV-1-infected men. AIDS. 2002;16:1698-1700.
10. Solas C, Lafeuillade A, Halfon P, et al. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency. Antimicrob Agents Chemother. 2003;47:238-243.
11. Lafeuillade A, Solas C, Chadapaud S, et al. HIV RNA levels, resistance, and drug diffusion in semen versus blood in patients receiving a lopinavir-containing regimen. JAIDS. 2003; 32:462-464.
12. Ghosn J, Chaix ML, Peytavin G, et al. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS. 2004;18:1958-1961.
13. Salzano FM, Bortolini MC. The Evolution and Genetics of Latin American Populations. Cambridge: Cambridge University Press; 2002.
14. Reis M, Santoro A, Suarez-Kurtz G. Thiopurine methyltransferase phenotypes and genotypes in Brazilians. Pharmacogenetics. 2003;13:371-373.
15. Suarez-Kurtz G. Pharmacogenomics in admixed populations. Trends Pharmacol Sci. 2005;26:196-201.
16. Leibenguth P, Le Guellec C, Besnier JM, et al. Therapeutic drug monitoring of HIV protease inhibitors using high-performance liquid chromatography with ultraviolet or photodiode array detection. Ther Drug Monit. 2001;23:679-688.
17. Wu EY, Wilkinson JM 2nd, Naret DG, et al. High-performance liquid chromatographic method for the determination of nelfinavir: a novel HIV-1 protease inhibitor in human plasma. J Chromatogr B Biomed Sci Appl. 1997;695:373-380.
18. Hornung RW, Reed LD. Estimation of average concentration in the presence of nondetectable values. Appl Occup Environ Hyg. 1990;5:46-51.
19. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS. 2000;14:237-242.
20. Sankatsing SU, Beijnen JH, Schinkel AH, et al. P-glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob Agents Chemother. 2004;48:1073-1081.
21. Hsu A, Granneman GR, Bertz RJ. Ritonavir: clinical pharmacokinetics and interaction with other anti-HIV agents. Clin Pharmacokinet. 1998;35:275-291.
22. Boffito M, Hoggard PG, Lindup WE, et al. Lopinavir protein binding in vivo through the 12-hour dosing interval. Ther Drug Monit. 2004;26:35-39.
23. Choo EF, Leake B, Wandel C, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000;28:655-660.
24. Huisman MT, Smit JW, Wiltshire HR, et al. P-glycoprotein limits oral availability. brain. and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol. 2001;59:806-813.
25. Vishnuvardhan D, Moltke LL, Richert C, et al. Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. AIDS. 2004;17:1092-1094.
26. Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75:13-33.
27. Fang CT, Hsu HM, Twu DJ, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis. 2004;190:879-85.